# US 12,180,506 B2 · Methods for promoting proliferation and propagation of stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,506 B2
- Document ID: US12180506B2
- Status: Granted
- Kind: B2
- Application number: 17/235,777
- Filed: 2021-04-20
- Published: 2022-04-07
- Granted: 2024-12-31
- Earliest claimed: 2020-10-05
- Assignees: Mycomagic Biotechnology Co., Ltd.
- Applicants: Mycomagic Biotechnology Co., Ltd.
- Inventors: Michael Lee
- Web page: https://patentgrep.com/patent/US12180506B2

## CPC

- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 2501/998: Proteins not provided for elsewhere
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides a method for proliferating or propagating undifferentiated stem cells, comprising contacting a population of stem cells with an effective amount of Ganoderma immunomodulatory protein or a recombinant thereof or a fragment thereof.

## Claims

### Claim 1

A method for proliferating or propagating undifferentiated stem cells, comprising contacting a population of stem cells with an effective amount of a Ganoderma immunomodulatory protein or an effective fragment thereof
wherein the Ganoderma immunomodulatory protein comprises an amino acid sequence as the amino acid sequence set forth in any one of SEQ ID NO: 3 and SEQ ID NO: 4; the effective fragment of Ganoderma immunomodulatory protein comprises an amino acid sequence set forth in any one of SEQ ID NO: 1 and SEQ ID NO: 2; and
wherein the stem cells comprise embryonic stem cells, mesenchymal stem cells (MSC), or tissue-specific stem cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the stem cells remain undifferentiated after the propagation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Ganoderma immunomodulatory protein comprises an amino acid sequence of SEQ ID NO: 3.

### Claim 4 (depends on 1)

The method of claim 1, wherein the Ganoderma immunomodulatory protein comprises an amino acid sequence of SEQ ID NO: 4.

### Claim 5 (depends on 1)

The method of claim 1, wherein an amino acid sequence of the effective fragment of Ganoderma immunomodulatory protein is selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the effective amount of the Ganoderma immunomodulatory protein or the effective fragment thereof is less than 15 μg/mL.

### Claim 7 (depends on 1)

The method of claim 1, wherein the effective amount of the Ganoderma immunomodulatory protein or the effective fragment thereof is less than 12.5 μg/mL.

### Claim 8 (depends on 1)

The method of claim 1, wherein the effective amount of the Ganoderma immunomodulatory protein or the effective fragment thereof ranges from about 1.0 μg/mL to about 15 μg/mL.

### Claim 9 (depends on 1)

The method of claim 1, wherein the effective amount of the Ganoderma immunomodulatory protein or the effective fragment thereof ranges from about 1.5 μg/mL to about 12.5 μg/mL.

### Claim 10 (depends on 1)

The method of claim 1, wherein the effective amount of the Ganoderma immunomodulatory protein or the effective fragment thereof ranges from about 1.5 μg/mL to about 6.5 μg/mL.

### Claim 11 (depends on 1)

The method of claim 1, wherein the population of the stem cells is of human origin.

### Claim 12 (depends on 1)

The method of claim 1, wherein the mesenchymal stem cells are adipose tissue-derived mesenchymal stem cells or bone marrow-derived mesenchymal stem cells.